Everolimus Results Improve for SEGA in Tuberous Sclerosis Everolimus Results Improve for SEGA in Tuberous Sclerosis

The EXIST-1 extension trial shows that rates of response to treatment with everolimus improved after 4 years in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news